United States Biodefense-Related Rapid Pathogen Identification and Treatments Markets Outlook Report: Data from 2019-2020, estimates for 2021 and CAGR projections to 2026
November 12, 2021 05:13 ET
|
Research and Markets
Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) -- The "The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments 2021-2026" report has been added to ResearchAndMarkets.com's...
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
June 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
VaxInnate Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets
May 13, 2015 08:00 ET
|
Scienta Communications
Cranbury, NJ, May 13, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced two strategic
promotions and two additions to...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
April 07, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
February 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
December 08, 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
August 26, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
August 20, 2013 11:21 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...